SS-31 (Elamipretide): Mitochondrial-Targeted Peptide Research
Mar 14, 2026·4 min read
Background
SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2), also known as elamipretide and formerly as Bendavia, is a synthetic tetrapeptide designed to selectively target the inner mitochondrial membrane. The compound was developed by Hazel Szeto and Peter Bhatt at Cornell University, and its name derives from the Szeto-Schiller peptide series. SS-31 is cell-permeable and concentrates in mitochondria at concentrations approximately 1,000- to 5,000-fold higher than in the cytoplasm, as documented through fluorescence microscopy studies using labeled analogs.
The peptide's mitochondrial targeting is driven by its alternating aromatic-cationic motif (aromatic-cationic-aromatic-cationic), which facilitates electrophoretic accumulation across the mitochondrial membrane potential without requiring active transport mechanisms.
Cardiolipin Interaction
The primary molecular target of SS-31 within mitochondria is cardiolipin, a phospholipid found exclusively in the inner mitochondrial membrane. Birk et al. (2013), publishing in the Journal of the American Chemical Society, demonstrated that SS-31 binds cardiolipin through a combination of electrostatic and hydrophobic interactions. Using surface plasmon resonance and fluorescence spectroscopy, the researchers characterized the binding affinity and stoichiometry of the SS-31-cardiolipin interaction.
Cardiolipin plays a critical structural role in organizing the electron transport chain complexes and maintaining cristae architecture. It is required for the proper function of Complexes I, III, IV, and V (ATP synthase), and for the formation of respiratory supercomplexes. SS-31's interaction with cardiolipin is hypothesized to stabilize cristae structure and optimize electron transport chain efficiency.
Barth Syndrome Clinical Trial
Barth syndrome is a rare X-linked genetic disorder caused by mutations in the TAFAZZIN gene, which encodes the enzyme responsible for cardiolipin remodeling. The resulting abnormalities in cardiolipin composition lead to mitochondrial dysfunction, cardiomyopathy, and skeletal myopathy.
Reid Thompson et al. (2021), publishing in Genetics in Medicine, reported results from a Phase 2/3 randomized, double-blind, placebo-controlled crossover trial of elamipretide in Barth syndrome patients. Twelve subjects were randomized to receive 40 mg per day of elamipretide or placebo subcutaneously for 12 weeks, followed by a 4-week washout period and crossover. An open-label extension continued for an additional 36 weeks.
While the primary endpoint during the 12-week blinded phase did not reach statistical significance, results at 36 weeks in the open-label extension showed improvements in the 6-Minute Walk Test (mean increase of 95.9 meters) and in the Barth Syndrome Symptom Assessment scale. The compound was generally well-tolerated, with injection site reactions as the most commonly reported adverse event.
Elamipretide received FDA approval in September 2025 for the treatment of Barth syndrome.
Preclinical Cardiac Research
Szeto (2014), publishing in the British Journal of Pharmacology, reviewed preclinical evidence for SS-31 in cardiac ischemia-reperfusion injury models. The review summarized studies demonstrating that pre-treatment with SS-31 reduced infarct size in rodent models of myocardial ischemia, as measured by triphenyltetrazolium chloride staining and cardiac enzyme release. The protective effect was associated with preservation of mitochondrial membrane potential and reduced production of reactive oxygen species during reperfusion.
These preclinical observations were obtained using established ischemia-reperfusion protocols including Langendorff isolated heart preparations and in vivo coronary artery ligation models.
Laboratory Handling Notes
SS-31 is supplied as a lyophilized powder and should be stored at -20°C in a desiccated environment. The peptide is soluble in water and DMSO. Researchers should be aware that SS-31 contains a dimethyltyrosine residue that is sensitive to oxidation; solutions should be prepared fresh and protected from light.
All findings discussed in this article are derived from peer-reviewed investigations. This compound is intended for research applications only.
References
- Birk, A.V., et al. "The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin." Journal of the American Chemical Society 135.40 (2013): 15019-15024.
- Reid Thompson, W., et al. "A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism." Genetics in Medicine 23.3 (2021): 471-478.
- Szeto, H.H. "First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics." British Journal of Pharmacology 171.8 (2014): 2029-2050.
- Zhao, K., et al. "Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury." Journal of Biological Chemistry 279.33 (2004): 34682-34690.
